Eye on Pharma: Similis Bio Launch, Biocon Biologics Sets Sights on Malaysian Biosimilar Market

May 19, 2022

New biosimilars are on the way, as JSR Life Sciences launches its business division (Similis Bio) that will improve efficiency and costs related to biosimilar development and Biocon Biologics signs a contract for commercialization in Malaysia.

Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars
Teva’s Lucentis Biosimilar Gains UK Approval
Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability
Alvotech Announces Positive Phase 1 Results for Ustekinumab Biosimilar